Rate My Professor Mark Harris

In 2018, Harris was a key member of the T1D Research Team at the UQ Diamantina Institute, alongside Professor Ranjeny Thomas and Ahmed Mehdi, which was named a finalist for the Johnson & Johnson Eureka Prize for Innovation in Medical Research for developing a method to identify infants at high risk of type 1 diabetes via peripheral blood gene activation patterns. He has supervised higher degree research projects at UQ, including studies on islet-specific T cell responses in type 1 diabetes, monogenic disorders of glucose-stimulated insulin secretion, and biomarkers in peripheral blood predictive of clinical type 1 diabetes. Key publications include 'Growth During Pubertal Induction in Girls With Turner Syndrome: A Retrospective Cohort Study' (2024), 'Circulating biomarkers during progression to type 1 diabetes' (2023), 'An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes' (2019), 'Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing in Maturity-Onset Diabetes of the Young' (2019), 'A peripheral blood transcriptomic signature predicts autoantibody development in infants at-risk for type 1 diabetes' (2018), 'Clinical usefulness of comprehensive genetic screening in maturity-onset diabetes of the young (MODY)' (2018), 'Gender Bias in Children Receiving Growth Hormone Treatment' (2010), and 'Reactivated CD4+Tm Cells of T1D Patients and Siblings Display an Effector Memory Bias' (2015). His contributions have advanced paediatric endocrinology, particularly in diabetes management and genetic diagnostics.